anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants are receiving two applications of 1% permethrin shampoo, which is the current drug of choice for Pediculosis capitis, on days 0 and 7. This group is defined as a control group.
Exercise will be used to induce and maintain weight loss in a 26-week Weight Management Program. Each subject will follow an aerobic exercise prescription of moderate intensity (60-75% maximum heart rate) to expend 2000-3000 kcal/week, lasting 30-60 minutes each session (over 5-7 sessions). Subjects will be instructed by sports trainers, compliance reviewed and adjusted if necessary to maintain the targeted total energy expenditure to produce weight loss of at least 7% over 26 weeks.
A standardized meal consisting of 2 slices of toast bread, organic peanut butter and jam was given to the participant. One and a half hours later, the participant ingested a caffeinated drink (3 mg per kg body weight of caffeine powder dissolved in water). After 30 mins, resting EE was measured using FM for 15 min while seated on the comfortable seat, and then for 5 min while seated on a cycle ergometer. Participants were then asked to pedal at 60 revolutions per minute (rpm) for 5 min per load at 20 watts (W), 35W, 50W, 65W, 80 W respectively. During cycling, EE was being measured using the FM, HR was monitored and rating of perceived exertion (RPE) was recorded in the last minute of every load cycle.
The invention relates to an oral liquid process capable of preventing and alleviating the diabetes, wherein the oral liquid has no side-effects on the human body. To prevent and alleviate the diabetes, the invention puts forward a formula with unique and effective components. Based on the broad research, people realize that the chromium, the magnesium and the kalium are necessary to the prevention and alleviation of the diabetes. Therefore, the invention provides the process for producing innoxious choromium, magnesium and kalium supplement medicaments. The simple production method of the chromium citrate medicament is characterized in that the chromium trichloride is taken as the raw material, made a chemical reaction to produce the chromic carbonate, and then made a reaction with the citric acid to produce the chromium citrate of the invention. With the same principle, the magnesiym chloride and the potassium hydroxide are taken as the raw materials to respectively produce the magnesium citrate and the kalium citrate, then the three are mixed in a appropriate quantity to produce the organic oral liquid. The organic chromium, organic magnesium and organic kalium in the product have no side-effects. The product is a liquid product and can make the contents of micro-chromium, micro-magnesium and micro-kalium be accurate.
Prolongation of the template bleeding time has been reported during continuous intravenous infusion of aminocaproic acid at dosages exceeding 24 g/day. Platelet function studies in these patients have not demonstrated any significant platelet dysfunction. However, in vitro studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) aminocaproic acid inhibits ADP and collagen-induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner. Following a 10 g bolus of aminocaproic acid, transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained. The concentration of aminocaproic acid necessary to maintain inhibition of fibrinolysis is 0.99 mMol/L or 0.13 mg/mL. Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of 0.13 mg/mL. Thus, concentrations which have been obtained in vivo clinically in patients with normal renal function are considerably lower than the in vitro concentrations found to induce abnormalities in platelet function tests. However, higher plasma concentrations of aminocaproic acid may occur in patients with severe renal failure.
TWP will adhere to a lower rating (less than or equal to 55 of a possible 75 points) on the Supported Employment Fidelity Scale rated by the National Fidelity Monitor. The TWP specialist participates in face-to-face supervision with the local Compensated Work Therapy (CWT) team according to the CWT manager's schedule.
1494856 Hydrolysis of proteins AFP CONSULTANTS Ltd 4 Aug 1976 [6 Aug 1975] 32875/75 Heading C3H A process of treating a protein-containing material comprises mixing together the proteincontaining material and an acid, the amount of acid being in excess of the stoichiometric amount required to completely convert the protein into its amino acid constituents, heating and agitating the mixture at atmospheric or greater than atmospheric pressure, recovering acid from the hydrolysate liquor before or after removing insoluble material from the mixture, partially or completely neutralizing any residual acid in the hydrolysate liquor, and recycling the recovered acid, the recycled acid being mixed with fresh protein-containing material. The hydrolysate liquor may be neutralized to a pH of 3À5-7À0. The acid used is preferably hydrochloric acid, sulphuric acid or phosphoric acid. The neutralization is preferably carried out by using sodium carbonate or sodium hydroxide. Sodium chloride may be added either before or after the hydrolysis. Apparatus is described for carrying out the process either batchwise or as a continuous process.
Participants receive ixazomib PO (orally) on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Drowsiness occurs in over 20% of patients treated with PRUDOXIN® Cream, especially in patients receiving treatment to greater than 10% of their body surface area. Patients should be warned about the possibility of sedation and cautioned against driving a motor vehicle or operating hazardous machinery while being treated with PRUDOXIN® Cream.

The sedating effects of alcoholic beverages, antihistamines, and other CNS depressants may be potentiated when PRUDOXIN® Cream is used.

If excessive drowsiness occurs it may be necessary to reduce the frequency of applications, the amount of cream applied, and/or the percentage of body surface area treated, or discontinue the drug. However, the efficacy with reduced frequency of applications has not been established.

Keep this product away from the eyes.
The following 2 treatment strategies are available. (1) DCB combined with provisional DES implantation 1-2 mm distally to the lesion ostium whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the lesion ostium followed by DCB (DES+DCB strategy).
The present invention relates to a novel metallo-beta-lactamase (MBL) inhibitor of formula I and an antibacterial composition comprising the same for the treatment of multi-drug resistant bacteria. In particular, the present invention relates to 3, 5-dichlorophenyl boric acid, (4- (4-amino-3-chlorophenoxy) -3, 5-dichlorophenyl) boric acid and (3, 5-dichloro-4- (2-hydroxyethoxy) phenyl) boric acid. The compounds of formula I according to the invention have inhibitory activity against a broad spectrum of metallo-beta-lactamases. By administering the MBL inhibitors of the invention together with a beta-lactam antibiotic agent, the antibiotic agent can be protected from degradation by the MBL produced by the microorganism. Thus, the time and range of antimicrobial activity can be extended or expanded. Some bacteria that are resistant to the antimicrobial agent due to the presence of MBL can be controlled by the compositions of the invention. Thus, the present invention is useful for treating or preventing infections with bacteria resistant to antibiotics.
PURPOSE:A kneading solution for dental ceramic material preventing flow and shape collapse in terms of piling operation and condensation, making piling operation easy, contriving to shorten piling time, by adding sodium glycolate to water, purified water, an alcohol and glycerin. CONSTITUTION:Sodium glycolate is added to one or more of water, purified water, an alcohol and glycerin to give a kneading solution. A dental ceramic material of ceramic powder of alumina type is kneaded with the kneading solution and piling is carried out by an operator such as doctor, dental technician, etc., by applying and piling on a model with a brush. Repeatedly applied pile, etc., is condensed, operation to close meshes of powder is carried out, piling is finished and the pile is removed from a mold, etc., and calcined to give an artificial tooth. EFFECT:Strength is increased after completion of piling, water can be used for brush washing and operation can be carried out readily and at low cost. Drying is slow, a top coat is compatible with a substrate when the top coat is repeatedly applied to the substrate especially in manufacture of a great number of teeth of long span and artificial teeth are readily manufactured.
OBJECTIVE: The aim of this study was to examine bereavement support for siblings of patients who die in the neonatal intensive care unit (NICU) given the adverse effects of unprocessed grief and the paucity of information on children whose newborn siblings die STUDY DESIGN:  This was an anonymous online original survey assessing pre-COVID-19 pandemic bereavement services for NICU families, clinicians' attitudes toward support interventions, challenges, and center characteristics. In spring 2020, nurse managers at 81 U.S. centers with neonatology and maternal-fetal medicine fellowship programs were asked to identify the individual most knowledgeable in their NICU's bereavement support services; these individuals were invited by email to complete an original online survey. Chi testing and odds ratios (ORs) compared responses from centers reporting involvement of palliative care teams (PCT) in NICU sibling bereavement versus no PCT.
RESULTS: Fifty-six percent (45 of 80) of invitees responded. Most (77%) NICUs permitted perimortem sibling visitation. Challenges included sparse community resources and limited direct sibling contact. Sixty-nine percent (n = 31) of centers were grouped as PCT. PCT respondents reported eightfold higher chances of providing direct education to the sibling (OR, 7.7; 95% confidence interval, 1.7-34; p = 0.01). Views on appropriateness of sharing educational information with extended family, babysitters, and teachers did not differ. While notifying pediatricians of families experiencing NICU death was more common in PCT (p = 0.02), most respondents reported having "no individual responsible for such communications" (52% PCT vs. 100%, p = 0.001).
CONCLUSION: Despite limited direct contact with siblings of NICU patients who die, efforts are made to involve them in bereavement activities. Opportunities to support these children were identified. Where available, palliative care teams can help provide bereaved siblings with direct education. We recommend formalizing communication mechanisms to ensure that if a NICU patient dies and has surviving siblings, the outpatient physicians caring for these siblings are informed.
KEY POINTS: · Palliative care enhanced sibling support.. · Resource and visitation limits hinder support.. · Teams sporadically briefed siblings' physicians..
RATIONALE: Stress during childhood or adolescence increases vulnerability to psychiatric disorders in adults. In adult rodents, the delayed effects of stress can increase anxiety-like behavior. These effects, however, can be prevented with post-stress administration of corticosterone (CORT). The effectiveness of CORT in preventing adolescent stress-induced emotional behavior alterations in adulthood has yet to be investigated.
OBJECTIVES: Here, we investigated the interactions between early adolescent stress and exogenous corticosterone on adult social, aversive, and drug-seeking behavior in mice, which are translationally related to symptoms associated with psychiatric and substance abuse disorders.
METHODS AND RESULTS: A single administration of CORT in drinking water (400ug/mL) for 24 h after social defeat or context fear conditioning prevents defeat-induced social avoidance, alters fear processing, prevents adolescent stress-induced anhedonia, and prevents stress-potentiated morphine place preference in adulthood. Exogenous CORT did not immediately prevent stress-induced potentiation of morphine conditioned-place preference in adolescents but did so in adult mice. However, when administered to adolescent mice, CORT also prevented the incubation of morphine-conditioned place preference into adulthood. Lastly, exogenous CORT administration blunted endogenous corticosterone but was unrelated to freezing behavior during a fear test.
CONCLUSIONS: This is the first demonstration of adolescent post-stress CORT promoting socio-emotional resilience and preventing drug-seeking behavior. Our data suggest elevated corticosterone after a stress experience promotes resilience for at least 40 days across the developmental transition from adolescence to adulthood and is effective for socio-emotional and drug-seeking behavior. These results are critical for understanding how adolescent stress impacts emotional and drug-seeking behavior into adulthood.
Women randomised to this arm will not receive any Diclectin® before symptoms appear, and will be advised to commence treatment only at first sign of nausea. The starting dose of Diclectin® will be 20mg (2 tablets) at bedtime.
PURPOSE: The present systematic review and meta-analysis aimed at evaluating the effect of low dialysate sodium concentration on interdialytic weight gain (IDWG) in chronic hemodialysis patients.
METHODS: Studies were eligible for inclusion if they were English language papers published in a peer-reviewed journal and met the following inclusion criteria: (1) studies in adult patients (over 18 years of age), (2) included patients on chronic hemodialysis since at least 6 months; (3) compared standard (138-140 mmol/l) or high (> 140 mmol/l) dialysate sodium concentration with low (< 138 mmol/l) dialysate sodium concentration; (4) Included one outcome of interest: interdialytic weight gain. Medline, PubMed, Web of Science, and the Cochrane Library were searched for the quality of reporting for each study was performed using the Quality Assessment Tool of Controlled Intervention Studies of the National Institutes of Health. The quality of reporting of each cross-over study was performed using the Revised Cochrane Risk of Bias (RoB) tool for cross-over trials as proposed by Ding et al. RESULTS: Nineteen studies (710 patients) were included in the analysis: 15 were cross-over and 4 parallel randomized controlled studies. In cross-over studies, pooled analysis revealed that dialysate sodium concentration reduced IDWG with a pooled MD of - 0.40 kg (95% CI - 0.50 to - 0.30; p < 0.001). The systematic review of four parallel, randomized, studies revealed that the use of a low dialysate sodium concentration was associated with a significant reduction of the IDWG in two studies, sustained and almost significant (p = 0.05) reduction in one study, and not significant reduction in one study.
CONCLUSION: Low dialysate sodium concentration reduces the IDWG in prevalent patients on chronic hemodialysis.
Sleep Scholar is a fully automated, single-session, self-guided, internet-based CBT-I intervention that participants will read from a web browser on their electronic device. Sleep Scholar's content was adapted from Ellis and colleague's, Morin's, and Perlis and colleague's protocols for therapist-guided CBT-I interventions. Sleep Scholar will be completed in approximately 30 minutes and consists of three successive text-based modules: Sleep Education, Initiating Sleep, and Enhancing Sleep Quality. New content (e.g., vignettes and quizzes) was created to tailor the intervention to college students. For example, after each module, short multiple choice and/or true-false question will be administered to assess participants' understanding of Sleep Scholar's strategies. Participants will be automatically provided feedback on their responses to ensure their understanding of Sleep Scholar's strategies.
Devices, systems and methods are disclosed which relate to collecting and distributing medical diagnostics using a smart card. A smart card with secure medical diagnostics logic on the memory is disclosed. When the smart card is inserted into a wireless communications device, the smart card receives data from a wireless medical diagnostic device. The wireless medical diagnostic device can be wearable by a user. The smart card stores the data in a medical diagnostics database on the smart card memory. A doctor or other medical professional may access the data in the medical diagnostics database after providing authentication.
PROBLEM TO BE SOLVED: To provide a cosmetic excellent in moisture retention.SOLUTION: The cosmetic contains cellulose acetate with a total degree of substitution of acetyl group of 0.4 to 1.2. As the cellulose acetate, cellulose acetate with a total degree of substitution of acetyl group of 0.5 to 1.1 is preferable. And the composition distribution index (CDI) defined by the following of the cellulose acetate is preferred to be 1.0 to 2.0. CDI=(actual measurement of composition distribution half width)/(theoretical value of composition distribution half width) The actual measurement of composition distribution half width is the composition distribution half width obtained by performing HPLC analysis of cellulose acetate propionate obtained by propionylating all the residual hydroxyl groups of cellulose acetate (sample). DS is total degree of substitution of acetyl group. DPw is weight average degree of polymerization (a calculated value by GPC-light scattering method with cellulose acetate propionate obtained by propionylating all the residual hydroxyl groups of cellulose acetate (sample)).
Participants with HIV-1 orally received unblinded 50 mg DTG one tablet and blinded 300 mg 3TC. Each participant received one capsule per day of each intervention up to Week 24.
OBJECTIVES: The pandemic has affected over 182 million coronavirus disease 2019 (COVID-19) cases worldwide. Accumulated evidence indicates that anosmia is one of the significant characteristics of COVID-19 with a high prevalence. However, many aspects of COVID-19-induced anosmia are still far from being fully understood. The purpose of this review is to summarize recent developments in COVID-19-induced anosmia to increase awareness of the condition.
METHODS: A literature search was carried out using the PubMed, Embase, Web of Science, and Scopus. We reviewed the latest literature on COVID-19-induced anosmia, including mechanisms of pathogenesis, olfactory testing, anosmia as predictive tool, pathological examinations, imaging findings, affected factors, co-existing diseases, treatments, prognosis, hypothesis theories, and future directions.
RESULTS: The possible pathogenesis of COVID-19-induced anosmia may involve inflammation of the olfactory clefts and damage to the olfactory epithelium or olfactory central nervous system by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The D614G spike variant may also play a role in the increased number of anosmia patients. Anosmia may also be an essential indicator of COVID-19 spread and an early indicator of the effectiveness of political decisions. The occurrence and development of COVID-19-induced anosmia may be influenced by smoking behaviors and underlying diseases such as type 2 diabetes, gastroesophageal disorders, and rhinitis. Most patients with COVID-19-induced anosmia can fully or partially recover their olfactory function for varying durations. COVID-19-induced anosmia can be treated with various approaches such as glucocorticoids and olfactory training.
CONCLUSION: Anosmia is one of the main features of COVID-19 and the underlying disease of the patient may also influence its occurrence and development. The possible pathogenesis of COVID-19-induced anosmia is very complicated, which may involve inflammation of the olfactory clefts and damage to the olfactory epithelium or olfactory central nervous system.
During the first AER training condition, we will train all participants at an energy expenditure of 12 kcal/kg/wk (KKW). The target exercise intensity for the AER group will be 50%-70% of baseline V02max.
The present invention addresses a vitamin and a method for ameliorating psychotic and schizophrenic mental states that originate from biochemical imbalance.  Brain disturbances such as paranoia, delusions, and hallucinations can result from a systemic NAD-deficiency. Additionally, impairments in prostaglandin mechanisms and/or blood circulation can have damaging repercussions on brain chemistry. A combination of oral flush niacin, supplemented with sustained-release niacin, is employed in a suggested high-dose regime. The immediate-release form of nicotinic acid initiates a prostaglandin-mediated surge of blood flow primarily to the truncal and facial subcutaneous vessels. Patients also experience a benzodiazepine-like effect from the flush niacin, which is capable of quickly crossing the blood-brain barrier.  Anxiety and agitation are quelled within minutes of ingestion.
In most patients, the right lobe of the thyroid gland is larger than the left lobe. After a hemithyroidectomy, the remaining lobe grows by up to 30% to compensate for the loss. However, thyroxine replacement is still necessary for 22% to 60% of all patients. The aim of this study is to investigate whether a right-lobe hemithyroidectomy predisposes to a higher postoperative dose of levothyroxine.

Patients and Methods In a retrospective cohort study, 459 patients over the age of 18 years who underwent a hemithyroidectomy at the Department of General Surgery, Division of Endocrine Surgery and a follow-up (3-12 months post-surgery) visit at the thyroid outpatient clinic of the Department of Endocrinology and Metabolism between 1994 and 2018 were investigated. The study was approved by the local ethics committee and performed in accordance with the Declaration of Helsinki. The work has been reported in line with the STROCSS criteria. The patients were identified via data extraction from a university hospital-wide Research, Documentation and Analysis (RDA) database. In a second step, further information necessary for the analysis (ultrasound data on pre-surgery thyroid volume, pre-surgery TSH, side and date of hemithyroidectomy, surgery protocol, underlying thyroid disease, type and dosage of treatment, age, weight, height, thyrotropin (TSH), free T4 (fT4), free T3 (fT3)) were extracted from the internal electronic health record system. Patients who had either received radiation therapy had undergone previous thyroid surgery, surgery on the contralateral lobe, had pre-existing hypothyroidism, an autoimmune disease of the thyroid or were pregnant were excluded from the analysis. 33 patients were excluded due to additional surgery on the contralateral lobe resulting in a total of 426 patients. Pre-surgery ultrasound thyroid volume was calculated with the volumetric ellipsoid method (height × width × depth × correction factor 0.524).